Advertisement
UK markets close in 1 hour 45 minutes
  • FTSE 100

    8,034.31
    +10.44 (+0.13%)
     
  • FTSE 250

    19,696.52
    +97.13 (+0.50%)
     
  • AIM

    753.02
    +3.84 (+0.51%)
     
  • GBP/EUR

    1.1614
    +0.0025 (+0.22%)
     
  • GBP/USD

    1.2383
    +0.0033 (+0.26%)
     
  • Bitcoin GBP

    53,686.20
    +519.02 (+0.98%)
     
  • CMC Crypto 200

    1,420.87
    +6.11 (+0.43%)
     
  • S&P 500

    5,038.33
    +27.73 (+0.55%)
     
  • DOW

    38,347.22
    +107.24 (+0.28%)
     
  • CRUDE OIL

    81.52
    -0.38 (-0.46%)
     
  • GOLD FUTURES

    2,327.10
    -19.30 (-0.82%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    18,057.02
    +196.22 (+1.10%)
     
  • CAC 40

    8,082.57
    +42.21 (+0.52%)
     

How Gilead’s Drugs Performed in 3Q17

In 3Q17, Gilead Sciences’ (GILD) Viread generated revenues of $274 million, a ~10% fall YoY (year-over-year) and a ~9% fall QoQ (quarter-over-quarter).